Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
9 nM 11 nM 15 nM >10 μM >10 μM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MYDLbY5ie2ViQYPzZZk> MkfmNlQhcA>? MkHpTY5pcWKrdHnvckBw\iCFRFu0JIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gVoIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwNkDPxE1? M1L4[FI1PjRzMUCz
COLO205 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnqNWI4OiCq MoLiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> NYrpb4JUOjR4NEGxNFM>
U937 NU[0RYZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\0VYxtPzJiaB?= NWDnSYtxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkG0JO69VQ>? NF\Wd4MzPDZ2MUGwNy=>
MOLM13 NH;aU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hl[VczKGh? MWfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN NFHyW5czPDZ2MUGwNy=>
MOLM13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnzWJVlPzJiaB?= MmDERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? NUD0XIluOjR4NEGxNFM>
MDA-MB-435 M2S5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPHU5Z[OjRiaB?= NFnYZZFKSzVyPUCuNVYh|ryP NV;YRmQ2OTV6MEG4N|E>
K562 NWC4cmJ7S3m2b4TvfIlkKEG|c3H5 NFnSXYI6PiCq NIPhT2VFVVOR NWTaXZJTUUN3ME2yJO69VQ>? MYKyOFQyPzV4Nh?=
DU145 NV;XTY9[S3m2b4TvfIlkKEG|c3H5 MorPPVYhcA>? NF\oPXZFVVOR NI\DR3ZKSzVyPUeuOUDPxE1? MkTQNlQ1OTd3Nk[=
MDA-MB-231 M1y1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYeWEyKM7:TR?= NHrhblUzPCCq M3vZbWROW09? MonIR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl MnP5NlQ1OTd3Nk[=
MCF7 NX\sRmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\ENUDPxE1? MUKyOEBp NHr2S4VFVVOR MkXWR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl M3vFPVI1PDF5NU[2
MCF7 NIHwWFhMcW6jc3WgRZN{[Xl? M2DseVUh|ryP MYCyOEBp NW\FNGN[TE2VTx?= MUjJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy NWPie|ZWOjR2MUe1OlY>
MDA-MB-231 M1\2U2tqdmG|ZTDBd5NigQ>? NGO1bIg2KM7:TR?= M{frU|I1KGh? MVHEUXNQ Ml7JTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NVLt[3V3OjR2MUe1OlY>
MDA-MB-231 NGDudGxHfW6ldHnvckBCe3OjeR?= NYnhVpRzOS1zMDFOwG0> NF;sOoszPCCq Mo\3SG1UVw>? MVzkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? M3q2OVI1PDF5NU[2
MCF7 MoTYSpVv[3Srb36gRZN{[Xl? MoHENU0yOCEQvF2= NIrwR24zPCCq MmP2SG1UVw>? NUTLZXJl\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MXmyOFQyPzV4Nh?=
MDA-MB-231 MmLSSpVv[3Srb36gRZN{[Xl? Ml30NE42NTFizszN NYnId|EzPDhiaB?= MlLTSG1UVw>? MYToZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=> MlfaNlQ1OTd3Nk[=
MCF7 MkLYSpVv[3Srb36gRZN{[Xl? NEHmOJAxNjVvMTFOwG0> MnrBOFghcA>? M3nVSWROW09? MkXSbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> NUfZepE6OjR2MUe1OlY>
697 NVv1fWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DQWmlEPTB;MUS4MlM5KG6P MXLTRW5ITVJ?
P12-ICHIKAWA NVXESHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NTnBKSzVyPUm2MlA1KG6P NVHmPXNxW0GQR1XS
NB69 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G5NWlEPTB;MU[xMlghdk1? NXXlRmJGW0GQR1XS
EoL-1 NUjkVVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\1UmlEPTB;MUi3MlI3KG6P MnftV2FPT0WU
BHT-101 M2XnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzbIVKSzVyPUG5PE4zPSCwTR?= MlHYV2FPT0WU
SK-NEP-1 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P6TGlEPTB;MkKwMlAzKG6P M1v6dXNCVkeHUh?=
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn4TIZKSzVyPUKyNE4yQSCwTR?= NYG5cFNHW0GQR1XS
AsPC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW1TWM2OD1{NUKuOVMhdk1? NEPYOYZUSU6JRWK=
ES1 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LN[GlEPTB;MkW2MlI2KG6P MnT5V2FPT0WU
LAMA-84 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXScmRxUUN3ME2yOVgvOTlibl2= M3O2eXNCVkeHUh?=
MOLT-16 NELHbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHZcnJUUUN3ME2yOVgvPDlibl2= MkLEV2FPT0WU
ES7 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ5Mz6wPUBvVQ>? MmnQV2FPT0WU
KY821 M4q2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTKbGV[UUN3ME2zNVQvOSCwTR?= MWXTRW5ITVJ?
RT-112 M3PmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN{MT6wOUBvVQ>? M4TQeHNCVkeHUh?=
HL-60 NXz2eFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jiZmlEPTB;M{SwMlY3KG6P Mkf1V2FPT0WU
MOLT-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN2NT6xN{BvVQ>? MlPaV2FPT0WU
KARPAS-45 M3\Uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln4TWM2OD1|N{[uNVYhdk1? M4HrNHNCVkeHUh?=
SK-N-AS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDhTWM2OD1|OEeuPFMhdk1? NH76fVhUSU6JRWK=
CTB-1 NHHRUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17UZWlEPTB;NEC1MlAzKG6P M3ixW3NCVkeHUh?=
NKM-1 NILKeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn0Z5QyUUN3ME20NVEvQDlibl2= MX7TRW5ITVJ?
HTC-C3 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPHVldiUUN3ME20N|IvQTVibl2= NETqZoNUSU6JRWK=
BE-13 M3rDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3WXod4UUN3ME20OFQvOjdibl2= MVrTRW5ITVJ?
KOSC-2 NHfj[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELKfW1KSzVyPUS2Ok46KG6P NICxSXlUSU6JRWK=
NB14 M2\yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHHU21KSzVyPUS4N{42QCCwTR?= NYT5bItlW0GQR1XS
CAL-27 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvWe4FKSzVyPUS5OE42QSCwTR?= M13iNXNCVkeHUh?=
H9 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoThTWM2OD12OUWuOFMhdk1? NX3hSIlPW0GQR1XS
RS4-11 NHT2NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPhWWx2UUN3ME21NFQvPzNibl2= M3HPWXNCVkeHUh?=
PA-1 NEPPbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVyOT64OkBvVQ>? M3jRdnNCVkeHUh?=
MV-4-11 M2fIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD13MUOuPFUhdk1? NWjtOJFoW0GQR1XS
OS-RC-2 NHuzRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTV{MT62NkBvVQ>? MmLzV2FPT0WU
RPMI-8226 NV3sT|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTV{Nj64OkBvVQ>? MYrTRW5ITVJ?
HGC-27 M3f6Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjSVmlKSzVyPUW2OE46QSCwTR?= NFjmfoxUSU6JRWK=
CHP-212 M3vRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISz[ldKSzVyPUW5N{42QSCwTR?= NHzsTY1USU6JRWK=
NB10 NInIb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGN2ZKSzVyPUW5PU4yQCCwTR?= MkD1V2FPT0WU
HH NHG1OZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjzWJhKSzVyPUW5PU41OyCwTR?= NHrPOZZUSU6JRWK=
EW-16 NGLTO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;GUGlEPTB;NkCzMlUzKG6P NX\3SXJ6W0GQR1XS
ES8 NXnDOJJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZyNT6yNUBvVQ>? M3u4W3NCVkeHUh?=
HAL-01 M4jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpbnRKSzVyPU[wOU43PyCwTR?= NYfvPHhqW0GQR1XS
A204 NFz5ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HXW2lEPTB;NkOzMlkyKG6P M3Lpb3NCVkeHUh?=
MHH-PREB-1 NG\4O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HDbmlEPTB;NkO2Mlk6KG6P MXHTRW5ITVJ?
EM-2 M3Szbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZ3MD62OEBvVQ>? Mkn4V2FPT0WU
BV-173 M4D5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmxN4xvUUN3ME22OVIvPDhibl2= NYrIc|FHW0GQR1XS
ONS-76 NX75TmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjE[IdKSzVyPU[3O{45OiCwTR?= MYjTRW5ITVJ?
KM-H2 M2HScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHniXVdKSzVyPU[5OU42PCCwTR?= NX\mWXRuW0GQR1XS
D-263MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37wS2lEPTB;N{G3MlEzKG6P M2L5S3NCVkeHUh?=
ES3 NY[4eJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTd{OD65N{BvVQ>? NEPTNIlUSU6JRWK=
VA-ES-BJ M4nJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\RfmNKSzVyPUezNk4zPyCwTR?= MWTTRW5ITVJ?
NBsusSR MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\rRndnUUN3ME23OFIvQTlibl2= MlPkV2FPT0WU
NCI-H520 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXKTWM2OD15NE[uOVIhdk1? Mly4V2FPT0WU
ES5 NVH0bpdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHjTWM2OD15NUKuPEBvVQ>? NXXX[o1IW0GQR1XS
T-24 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPZUmhtUUN3ME23O|gvPzFibl2= MVHTRW5ITVJ?
SW962 NHXi[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f1VGlEPTB;OEC4MlY{KG6P M33QVnNCVkeHUh?=
EW-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTvTWM2OD16MEiuO|Yhdk1? MUfTRW5ITVJ?
RXF393 NWXKWIxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRThzMj63PUBvVQ>? NV32cpFyW0GQR1XS
U251 NXnBWodoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThzMz64PEBvVQ>? Ml7PV2FPT0WU
CAMA-1 M2PTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTh|Mz65OEBvVQ>? M3;nc3NCVkeHUh?=
JVM-3 M1\FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT3TnpKSzVyPUi1NU44QCCwTR?= MWTTRW5ITVJ?
COLO-800 M1fafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjk[5hKSzVyPUi5O{44QCCwTR?= M3fYdHNCVkeHUh?=
OVCAR-5 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO2TWM2OD17MECuNUBvVQ>? MXTTRW5ITVJ?
LB1047-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL1V|V{UUN3ME25NlcvPTZibl2= M{\vfnNCVkeHUh?=
SW954 NH73bHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuxcXNKSzVyPUmyPU41OSCwTR?= NEi2dZZUSU6JRWK=
J-RT3-T3-5 NYeyZWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XFbWlEPTB;OUO2MlA3KG6P MVvTRW5ITVJ?
Mewo MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHJeWN1UUN3ME25N|YvPiCwTR?= NWXtWpV[W0GQR1XS
NCI-H1770 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2wV2Z{UUN3ME25OFAvPTVibl2= M4XhenNCVkeHUh?=
HO-1-N-1 NV\FdFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfITWM2OD17NkKuPFEhdk1? MlnZV2FPT0WU
HSC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXRUnZKSzVyPUm2Ok41QCCwTR?= MUfTRW5ITVJ?
TYK-nu M{LF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTZPVFHUUN3ME25PVgvOjVibl2= MkT1V2FPT0WU
KYSE-150 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjBVnVKSzVyPUGuNFAxPzZizszN NU[3[WxiW0GQR1XS
SN12C MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMEC4O|Uh|ryP M2OzfXNCVkeHUh?=
MOLT-13 M1;tUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSxOYRsUUN3ME2xMlAyPDJzIN88US=> M2Llb3NCVkeHUh?=
TE-11 NYqxdIxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLnTWM2OD1zLkC0PFEzKM7:TR?= M2DyXXNCVkeHUh?=
DB NF;xZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwMEeyO|Mh|ryP NF75bGFUSU6JRWK=
CAL-39 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TpT2lEPTB;MT6wO|UzOiEQvF2= NFjTVmtUSU6JRWK=
A3-KAW MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwMEi0NFgh|ryP MlXQV2FPT0WU
CHP-134 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwMUG4NFch|ryP M{HH[nNCVkeHUh?=
TGW NVH4WWNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHETWM2OD1zLkGyN|k2KM7:TR?= MVzTRW5ITVJ?
QIMR-WIL M37K[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT1TWM2OD1zLkGzNVM1KM7:TR?= NXPmdnh7W0GQR1XS
NCI-SNU-1 M{K4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDYV482UUN3ME2xMlE3OzV2IN88US=> NEfOVXVUSU6JRWK=
CGTH-W-1 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fPc2lEPTB;MT6xO|E5PiEQvF2= M3;x[3NCVkeHUh?=
MHH-ES-1 M3HGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInObFlKSzVyPUGuNVc6QDZizszN M2C2N3NCVkeHUh?=
LB2241-RCC M1vJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jTfGlEPTB;MT6xPFYzKM7:TR?= MXzTRW5ITVJ?
ML-2 M3HuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkC3N|Qh|ryP M1XoWHNCVkeHUh?=
COR-L23 NH;IV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[5bWlEPTB;MT6yNlk{OyEQvF2= NHnSRllUSU6JRWK=
BFTC-905 NGPHSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXoTWM2OD1zLkK0NlY4KM7:TR?= MYnTRW5ITVJ?
Hs-578-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnhZ5FpUUN3ME2xMlI2QDF5IN88US=> MmnBV2FPT0WU
KG-1 NVLpd|ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnmboNKSzVyPUGuNlY3QDZizszN M4\6TXNCVkeHUh?=
HEL MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK5TWM2OD1zLkK5N|M5KM7:TR?= MULTRW5ITVJ?
A549 NIj4cGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrLZ4ZKUUN3ME2xMlI6Ozl7IN88US=> NFjRfIxUSU6JRWK=
COLO-741 NVLOOoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXSTWM2OD1zLkOyNFg6KM7:TR?= Mnj1V2FPT0WU
PC-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwM{WyNlEh|ryP NH7QOIRUSU6JRWK=
HOS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwM{WyPVYh|ryP MX\TRW5ITVJ?
HT-1080 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fZWmlEPTB;MT6zO|UyQSEQvF2= M3z3TnNCVkeHUh?=
TE-8 M{TWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XhUWlEPTB;MT60NVc4PCEQvF2= NG\x[lFUSU6JRWK=
BHY M4G2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO0UZZKSzVyPUGuOFY6OjNizszN M1rJ[XNCVkeHUh?=
BB65-RCC NUPlWJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTsVYtSUUN3ME2xMlUxPTJ6IN88US=> NE\KXZdUSU6JRWK=
HN NG\lXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD1zLkW0NFcyKM7:TR?= MXHTRW5ITVJ?
NCI-H441 M{DReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;sPIRyUUN3ME2xMlU1QTB5IN88US=> NF36XJpUSU6JRWK=
RPMI-8866 NIrqXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2niSWlEPTB;MT61PFUxPyEQvF2= M4npdXNCVkeHUh?=
CAL-62 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XUc2lEPTB;MT62NFg3OiEQvF2= MVLTRW5ITVJ?
MG-63 NIfGV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPTWM2OD1zLk[xPFE{KM7:TR?= NEnFS3RUSU6JRWK=
SK-LU-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ETnAxUUN3ME2xMlYzOTV{IN88US=> MmK1V2FPT0WU
BCPAP M2n2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwNk[0OVch|ryP NELW[lRUSU6JRWK=
22RV1 NUnNPWhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfjdJFKSzVyPUGuOlc5PDNizszN MWXTRW5ITVJ?
T47D NFjBUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknSTWM2OD1zLk[4NFYyKM7:TR?= MYXTRW5ITVJ?
MSTO-211H NEn4OWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1dVg5UUN3ME2xMlY6PjB|IN88US=> NXfmbGNDW0GQR1XS
DEL NVfCPHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS1b5pmUUN3ME2xMlcxOjd|IN88US=> MmjpV2FPT0WU
H4 NF;sOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD1zLkezNlEzKM7:TR?= M3rBUHNCVkeHUh?=
CAL-51 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwN{S4OVUh|ryP NVPJOYlVW0GQR1XS
ABC-1 M4rNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwN{i1PFIh|ryP NULWelREW0GQR1XS
MZ2-MEL NV7EOYlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBO4FKSzVyPUGuO|k2PDJizszN Ml\YV2FPT0WU
YKG-1 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH74PVBKSzVyPUGuPFExPjFizszN NUHmWGF2W0GQR1XS
KM12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwOEG2NFIh|ryP NIfwOXpUSU6JRWK=
L-363 M2DLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnVdZVKSzVyPUGuPFc1OTJizszN Mn3JV2FPT0WU
KU812 NWm0enB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFwOEmyPFIh|ryP NFHQSFhUSU6JRWK=
LOXIMVI MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Ll[mlEPTB;MT65NVIzQCEQvF2= NF;sbGRUSU6JRWK=
G-401 NYnGbIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PSe2lEPTB;MT65NlQzQCEQvF2= M2SxbnNCVkeHUh?=
SW780 NXTGcXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD1zLkm2NlQ3KM7:TR?= NHOzSmhUSU6JRWK=
SW872 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjreI5KSzVyPUGuPVg{OyEQvF2= NILQbHZUSU6JRWK=
NB7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwOUmzNlMh|ryP MoHDV2FPT0WU
T98G M1uySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzSPFJKSzVyPUKuNFA3PjZizszN M2iyUXNCVkeHUh?=
SW1710 NIPQU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDwTWM2OD1{LkC2PVQ2KM7:TR?= NV[zcWZyW0GQR1XS
NCI-H1573 M1;CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf0c5IzUUN3ME2yMlA4Ojl6IN88US=> NF3lT5ZUSU6JRWK=
KE-37 NHzRU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\hPGlEPTB;Mj6wPFk2OSEQvF2= MXXTRW5ITVJ?
786-0 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDrNmVGUUN3ME2yMlE2PDN7IN88US=> MULTRW5ITVJ?
SAS M4jWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwMkCzO|Qh|ryP M1\yXnNCVkeHUh?=
CAL-54 M1SwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwMkC0NVMh|ryP MmfVV2FPT0WU
SF268 M3zBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW5VIlrUUN3ME2yMlI{OTJ{IN88US=> NG\CZYNUSU6JRWK=
SW620 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfiTWM2OD1{LkK2NVY6KM7:TR?= NGLRfJlUSU6JRWK=
MN-60 NYrQR5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;5co5TUUN3ME2yMlMyODZizszN NF7wSnRUSU6JRWK=
EFO-27 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[xU|RKSzVyPUKuN|IxPThizszN NYn6WWRtW0GQR1XS
NCI-H747 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1{LkOyNVk6KM7:TR?= MUHTRW5ITVJ?
HCC2218 NGrNW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L0dWlEPTB;Mj6zOVM4PCEQvF2= NXHrbIQ4W0GQR1XS
MIA-PaCa-2 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7BRooxUUN3ME2yMlM3PDN5IN88US=> NGj4fldUSU6JRWK=
SJSA-1 NGH3[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJwM{e3PVYh|ryP MUXTRW5ITVJ?
RKO NXX2[VlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL3SWE4UUN3ME2yMlM5PDl4IN88US=> MWnTRW5ITVJ?
NB6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\yfoJKSzVyPUKuOFA{PzRizszN M2fBV3NCVkeHUh?=
ES4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jHfmlEPTB;Mj60OVQzOiEQvF2= MXjTRW5ITVJ?
EGI-1 NXTTVVlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi4T|NWUUN3ME2yMlQ3QDh|IN88US=> NIPMSIlUSU6JRWK=
CTV-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TlfmlEPTB;Mj61Nlc4OyEQvF2= NIn5UZRUSU6JRWK=
NCI-H1355 M4fZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSzVnZKSzVyPUKuOVU6PTFizszN NFzROXhUSU6JRWK=
GT3TKB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;B[2lEPTB;Mj61PVE6QSEQvF2= MX3TRW5ITVJ?
SK-HEP-1 NUjSOmVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwNUmyOlYh|ryP M4jKRnNCVkeHUh?=
GAMG NIW5WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTufWNFUUN3ME2yMlU6Ozl2IN88US=> M3y5[XNCVkeHUh?=
SK-MES-1 NWPOXWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTmN2xKSzVyPUKuOlE5ODNizszN MVXTRW5ITVJ?
RO82-W-1 NGfXc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TJNGlEPTB;Mj62NlA2PyEQvF2= Mmn6V2FPT0WU
ECC10 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3wcpBKSzVyPUKuO|AzODZizszN M2XwOnNCVkeHUh?=
MCF7 M1;K[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\TTWM2OD1{LkexOFY1KM7:TR?= M3W3NHNCVkeHUh?=
D-283MED NHK0W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmzTWM2OD1{LkeyOFMh|ryP M{LJdnNCVkeHUh?=
RPMI-7951 NWnnR3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxN5dRUUN3ME2yMlc2Pjl2IN88US=> NWrMVpRzW0GQR1XS
Ramos-2G6-4C10 NWThS3U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5OWpmUUN3ME2yMlc4ODl7IN88US=> NEXhcINUSU6JRWK=
KGN NE\he|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljPTWM2OD1{LkixPFg1KM7:TR?= NHvOUXlUSU6JRWK=
NUGC-3 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJwOEK1NFUh|ryP M{e5R3NCVkeHUh?=
NCI-H292 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwOEWwOVMh|ryP NVzYdmo4W0GQR1XS
Becker NH\3[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3qxeWlEPTB;Mj65OVg{OiEQvF2= NU[wbWlGW0GQR1XS
NCI-H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fRVWlEPTB;Mz6wOVI3OyEQvF2= NIW0V4JUSU6JRWK=
ETK-1 NXru[mRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fwRWlEPTB;Mz6wOVQ{KM7:TR?= M2DvWnNCVkeHUh?=
TK10 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jsOWlEPTB;Mz6yNFE3PSEQvF2= MoHTV2FPT0WU
VMRC-RCZ MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELtNlFKSzVyPUOuN|Y1QDhizszN NF:5VWlUSU6JRWK=
YH-13 NEXuXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\IU5ZwUUN3ME2zMlQ1ODd7IN88US=> NGj0ZVVUSU6JRWK=
DU-145 M1PBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6cGlEPTB;Mz60OlI3QSEQvF2= M2DiS3NCVkeHUh?=
SW1088 NGPTd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP5NnhOUUN3ME2zMlQ4PDdizszN NFHGfWJUSU6JRWK=
HOP-92 MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3XTWM2OD1|LkWwN|QzKM7:TR?= MYnTRW5ITVJ?
KP-N-YS M{jLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPVfYxKSzVyPUOuOlIyOzlizszN M2r6NXNCVkeHUh?=
NCI-H460 MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZWIVOUUN3ME2zMlY3PzNizszN NWjpR3YxW0GQR1XS
U-2-OS M2HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LB[GlEPTB;Mz63NlU{PSEQvF2= MXPTRW5ITVJ?
A101D NELVd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfGflFoUUN3ME2zMlc3QTN4IN88US=> NGfrNmVUSU6JRWK=
MDA-MB-231 NYrMT5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwOEG5OVEh|ryP MYDTRW5ITVJ?
IST-MES1 NF3UdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;NTWM2OD1|LkizNkDPxE1? NXPacYJvW0GQR1XS
COR-L105 M1GyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRwMEG4JO69VQ>? M3fkUnNCVkeHUh?=
NCI-H1437 NHK0UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjaNIJKSzVyPUSuNFI{ODJizszN NHf1eXpUSU6JRWK=
CAL-85-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzZNoxKSzVyPUSuNFI1PjFizszN M13pVHNCVkeHUh?=
MZ1-PC MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj1e4ZMUUN3ME20MlE5PTV4IN88US=> MkfXV2FPT0WU
VM-CUB-1 NHHiUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPhTWM2OD12LkOxNlg1KM7:TR?= MUjTRW5ITVJ?
CHL-1 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwM{KxOlkh|ryP MUDTRW5ITVJ?
MDA-MB-361 NH\zZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfiU3RYUUN3ME20MlM{OTV|IN88US=> MkjmV2FPT0WU
NCI-H661 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwNUCwPVIh|ryP MkLGV2FPT0WU
EW-11 NXvUWJdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwNUKyN|Eh|ryP MkLzV2FPT0WU
BEN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zmfWlEPTB;ND61NlgyPSEQvF2= NXq1ZpNnW0GQR1XS
BFTC-909 NUDGe3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLLPYo2UUN3ME20MlU3Ojd3IN88US=> NH\QWXRUSU6JRWK=
NCI-H2087 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwNUixOlQh|ryP NH3FTZpUSU6JRWK=
RVH-421 M1zL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHsW41KSzVyPUSuOlY3QSEQvF2= NFfZOIdUSU6JRWK=
P30-OHK MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn5THNTUUN3ME20MlY5ODB6IN88US=> NVLwZYpmW0GQR1XS
NCI-H28 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nq[WlEPTB;ND64NVY3OSEQvF2= MXLTRW5ITVJ?
ES6 NHexPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfYWmlKSzVyPUSuPFMxOTZizszN NWXTdZBrW0GQR1XS
769-P NWfVRYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS4NoFKSzVyPUSuPFU6OjZizszN M{nocnNCVkeHUh?=
OE33 NXz0W2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLJRmNqUUN3ME20Mlg5OTZzIN88US=> NIPwclNUSU6JRWK=
SW982 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XmdmlEPTB;ND65OVA3OSEQvF2= MorRV2FPT0WU
A388 NFLWXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0Z5pnUUN3ME21MlAzQTh|IN88US=> NYK5Z5FEW0GQR1XS
TI-73 NIXXSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwME[xPVQh|ryP NYrm[VdtW0GQR1XS
HCT-116 NVTKN5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j1emlEPTB;NT6wPVg5QSEQvF2= NYfkTGNmW0GQR1XS
HuP-T3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fMZWlEPTB;NT6xPFcxQSEQvF2= NI\rb2hUSU6JRWK=
G-402 NWLFNVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrETIpKSzVyPUWuNVk1OTZizszN M4j2PHNCVkeHUh?=
NCI-H1792 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SdnhKUUN3ME21MlI1PjJ{IN88US=> NFv6cG9USU6JRWK=
NCI-H209 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHvVIxKSzVyPUWuNlU6PDJizszN MXvTRW5ITVJ?
NCI-H1650 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e3OGlEPTB;NT6zNFY{PCEQvF2= M2r1dnNCVkeHUh?=
LCLC-97TM1 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD13LkOxPFA5KM7:TR?= NVvsOZhzW0GQR1XS
S-117 NV;xWZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTZNJVKSzVyPUWuN|Y6PzZizszN NYSyTVVrW0GQR1XS
GI-ME-N Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;u[GlEPTB;NT6zPVY5OSEQvF2= NWG2Wmt3W0GQR1XS
NCI-H2122 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnuVXJSUUN3ME21MlQ6Ozl5IN88US=> NEjke4dUSU6JRWK=
NCI-H1793 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33nb2lEPTB;NT62O|U6OyEQvF2= M{jtTHNCVkeHUh?=
C2BBe1 NVLT[lFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrsZWFKSzVyPUWuO|AxQDhizszN NEXq[5lUSU6JRWK=
TE-12 NV;KPWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTVwOEC1OVYh|ryP NUT1U2pyW0GQR1XS
LCLC-103H NIXtT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPlW5JKSzVyPUWuPVE4KM7:TR?= MY\TRW5ITVJ?
A673 NEj5OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTVwOUG5N|Ih|ryP NFPQZlVUSU6JRWK=
BB30-HNC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELUOHFKSzVyPUWuPVg{PiEQvF2= M3H2bXNCVkeHUh?=
SF295 NFXRdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTZwMEC0NlIh|ryP MVPTRW5ITVJ?
KU-19-19 M1Xuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP6eVlpUUN3ME22MlAyPzNzIN88US=> NFfzVmdUSU6JRWK=
CFPAC-1 M3rhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTG[HlVUUN3ME22MlA1PDR|IN88US=> NYnDVWx{W0GQR1XS
LoVo NHPSSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZwMEWwOlMh|ryP NVHwd5VZW0GQR1XS
8505C NHq4UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfyTWM2OD14LkC3OVc{KM7:TR?= MVXTRW5ITVJ?
GMS-10 NX\E[HZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XHR2lEPTB;Nj6xOVAxOiEQvF2= M33LR3NCVkeHUh?=
Ca9-22 NH20Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfzUHhKSzVyPU[uNVY4OSEQvF2= MnrYV2FPT0WU
DOK NUDrbphtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi3VFlKSzVyPU[uNlIxPzJizszN NGDmeZhUSU6JRWK=
FADU MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjz[HJKSzVyPU[uNlYxOzlizszN MYXTRW5ITVJ?
BxPC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXzSmpKSzVyPU[uNlc{OiEQvF2= MV\TRW5ITVJ?
CAL-33 M1\Yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofOTWM2OD14LkK5NlAyKM7:TR?= M3vqR3NCVkeHUh?=
SHP-77 NHTVdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVru[Vh7UUN3ME22MlMyPTF{IN88US=> MkfoV2FPT0WU
LXF-289 NWDRS4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTZwM{O0OVUh|ryP NUHxZW1pW0GQR1XS
GB-1 M3;MWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17IemlEPTB;Nj6zPFIh|ryP NWnMRlNoW0GQR1XS
KS-1 NYS0boZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwM{i0OFch|ryP MYHTRW5ITVJ?
D-502MG M1X3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrFbGlKSzVyPU[uOFI{PzZizszN NFHSZVlUSU6JRWK=
LAN-6 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HhNmlEPTB;Nj61NVAzOyEQvF2= MWLTRW5ITVJ?
H-EMC-SS Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrsTWM2OD14LkW2NVQ4KM7:TR?= NWjXWnUxW0GQR1XS
LC-2-ad NVe2TopYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XKWWlEPTB;Nj62NFA4PiEQvF2= MYjTRW5ITVJ?
NCI-H1693 NH[5XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjJeW5lUUN3ME22MlYzOjF3IN88US=> NE[3T|NUSU6JRWK=
SK-N-FI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXSTWM2OD14Lke1NFQ1KM7:TR?= NFfNOZBUSU6JRWK=
D-423MG M1HLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTZwN{[xNVch|ryP M3PlSnNCVkeHUh?=
KNS-42 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTzU3RKSzVyPU[uO|gyQTdizszN NG\STW1USU6JRWK=
GCT NXTTNppXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\CVGFKSzVyPU[uPVM5KM7:TR?= NYW5S4xlW0GQR1XS
DSH1 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTdwME[zN{DPxE1? MYjTRW5ITVJ?
D-247MG MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjxfnRKSzVyPUeuNFc5QDFizszN NVm1eYFyW0GQR1XS
NCI-SNU-5 NVj1WZRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;NS29jUUN3ME23MlE5OzdzIN88US=> M3K0WHNCVkeHUh?=
TE-6 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTdwMkC2NFEh|ryP MUPTRW5ITVJ?
NOMO-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTdwMkKxNlch|ryP MVHTRW5ITVJ?
NB17 NIn3b4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:zOGlEPTB;Nz6zNFMxQSEQvF2= NWDlWolmW0GQR1XS
EW-22 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnMTWM2OD15LkO0N|Q5KM7:TR?= NYLLXGpLW0GQR1XS
EW-13 M1;oOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwM{WxOlIh|ryP MoXhV2FPT0WU
DOHH-2 MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD15LkS0NFIh|ryP NFLqTWdUSU6JRWK=
TGBC1TKB NEXETFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrxRohKSzVyPUeuOFk5QTlizszN NUDIZY9TW0GQR1XS
GR-ST MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6NFJKSzVyPUeuOVI2QTRizszN M3;pc3NCVkeHUh?=
KYSE-520 NVHCfXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvrTId2UUN3ME23MlU2PTF3IN88US=> MXPTRW5ITVJ?
CAPAN-1 NHzLPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\BUJRCUUN3ME23MlU6PTFizszN NULWe|FmW0GQR1XS
HCE-4 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\rb3pKSzVyPUeuOlIzPzlizszN NWnx[Ic5W0GQR1XS
MLMA NVnIfJc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHmTWM2OD15Lk[yPVU4KM7:TR?= MlrUV2FPT0WU
HT-144 NYHF[o14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW1NXJJUUN3ME23MlY2OzZ6IN88US=> M4n1VXNCVkeHUh?=
KYSE-180 NV\uVmFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;WOGxKSzVyPUeuO|EyPjlizszN NYrV[nFRW0GQR1XS
TE-5 NEW0PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD15Lkm1PVcyKM7:TR?= MXLTRW5ITVJ?
IGROV-1 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC0bpVnUUN3ME23Mlk5PTVzIN88US=> NH7ZeoRUSU6JRWK=
NCI-H1581 NFm1PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r0VGlEPTB;OD6wNVIh|ryP NYjMTFRbW0GQR1XS
SW1990 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\QTWM2OD16LkC0OlU6KM7:TR?= MlztV2FPT0WU
EFM-19 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPicot5UUN3ME24MlA5PTR3IN88US=> NYfSWnZnW0GQR1XS
OGR-1 NHj5e21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPQeJpKSzVyPUiuOFMxOjNizszN MmPLV2FPT0WU
U-118-MG NH\SRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwNEO0OlMh|ryP M2\nXnNCVkeHUh?=
SK-OV-3 NEDyRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRThwNE[3OlUh|ryP NHfp[4lUSU6JRWK=
KNS-62 NXi4PVF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qyS2lEPTB;OD61NVc3OSEQvF2= MoezV2FPT0WU
GOTO MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SzT2lEPTB;OD61O|Y{PSEQvF2= NX6zS5RQW0GQR1XS
8305C MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn3ZYdbUUN3ME24MlcxPDh2IN88US=> NVHvNoZXW0GQR1XS
RPMI-2650 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO3NXBKSzVyPUiuO|E6PTVizszN NYrPN3Z4W0GQR1XS
NEC8 NEHSfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzTWM2OD16Lke0N|A4KM7:TR?= MknkV2FPT0WU
KYSE-450 M2H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLGTWM2OD16Lki2OVQ5KM7:TR?= NFf6[HJUSU6JRWK=
RMG-I M2\j[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrZ2lEPTB;OT6xOFA2QCEQvF2= NH\jZmhUSU6JRWK=
CAKI-1 M{O1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD17LkOxPVc6KM7:TR?= M4jDPHNCVkeHUh?=
KYSE-510 NVPae5FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTlwM{W3O|gh|ryP NXrRdG9zW0GQR1XS
A4-Fuk M{G1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTlwM{[3NFEh|ryP MoT5V2FPT0WU
AN3-CA NXjPWGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MVlJKSzVyPUmuOFU1PDRizszN MlLsV2FPT0WU
SK-N-DZ M2O5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfYUYZKSzVyPUmuO|I5PDlizszN NFvaXZRUSU6JRWK=
HSC-2 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTlwN{[2Nlkh|ryP NV31TWVyW0GQR1XS
EW-1 M1zvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LD[WlEPTB;OT63PVM3QSEQvF2= M4fDS3NCVkeHUh?=
D-566MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTlwOEO2OlQh|ryP MonYV2FPT0WU
COLO-792 NIr5VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrxUnVzUUN3ME25Mlk5PzR4IN88US=> M4DnbHNCVkeHUh?=
TE-10 M1OwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M365Z2lEPTB;MUCuNFM6PiEQvF2= NHHxT2xUSU6JRWK=
NCI-H650 NXzXZmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPsSmhKSzVyPUGwMlQzQDZizszN NWXBZmd[W0GQR1XS
U-266 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\uToJiUUN3ME2xNE41PTVizszN NVPndZV3W0GQR1XS
Detroit562 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e4[2lEPTB;MUGuNFUyPSEQvF2= M1jRcnNCVkeHUh?=
NH-12 NFfoUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrX[nlKSzVyPUGxMlE1PDZizszN NGDvXnpUSU6JRWK=
CO-314 NEm1XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fJ[mlEPTB;MUGuNlg1OiEQvF2= M1HYUnNCVkeHUh?=
IST-MEL1 M4O1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nKPGlEPTB;MUGuOVMzOyEQvF2= M{S0[XNCVkeHUh?=
KNS-81-FD NFr4epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH30TWVKSzVyPUGxMlU2OjdizszN Mm[2V2FPT0WU
SW1463 M2O5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XFOWlEPTB;MUGuOVk5QSEQvF2= NH65epBUSU6JRWK=
NCI-H23 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3FTWM2OD1zMT62OVUzKM7:TR?= MX;TRW5ITVJ?
SK-MEL-2 M2S4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD1zMT63NVk4KM7:TR?= NWW4e4Q{W0GQR1XS
NB13 M4jCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF{LkG0PVUh|ryP MnzyV2FPT0WU
Daoy NF3kVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPJNJZKSzVyPUGyMlI5PTZizszN NHvEdJBUSU6JRWK=
NCI-H1623 M{\Wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rOOGlEPTB;MUKuN|gxOSEQvF2= NHvJdHhUSU6JRWK=
NMC-G1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF{LkexO{DPxE1? M1XCUnNCVkeHUh?=
DK-MG M{C2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37QcmlEPTB;MUKuPVQ5OiEQvF2= NYPZdohrW0GQR1XS
TCCSUP NWPhTFZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1zMz6xNlg1KM7:TR?= M1;lZXNCVkeHUh?=
SCC-15 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF|LkK2OVEh|ryP M1nv[XNCVkeHUh?=
NOS-1 M1XnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHCO25KSzVyPUGzMlI5QTNizszN NH\Me2tUSU6JRWK=
RH-1 NHTOTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TvWmlEPTB;MUOuN|A{PyEQvF2= NIixVZBUSU6JRWK=
SK-MEL-3 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrYSJJKUUN3ME2xN{4{PzJ6IN88US=> M17kOHNCVkeHUh?=
NB5 M13YO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXzTWM2OD1zMz60NFY4KM7:TR?= MWXTRW5ITVJ?
SNU-387 NWrsOYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\kNmlEPTB;MUOuOVA4OiEQvF2= NWfyVXRNW0GQR1XS
CAL-120 M3vPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|Lk[3NVgh|ryP NYfSOGVtW0GQR1XS
Mo-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7DUoV5UUN3ME2xN{44ODdizszN NXzRNYZCW0GQR1XS
LNCaP-Clone-FGC M4fPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLkTm1uUUN3ME2xN{44QTl{IN88US=> MWTTRW5ITVJ?
CAN NW\aXndkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TPWWlEPTB;MUSuNFI5QCEQvF2= MoX5V2FPT0WU
SK-MEL-30 NFLHbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF2LkC2N{DPxE1? NFTtcJpUSU6JRWK=
COLO-678 NVLyVm14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33GOmlEPTB;MUSuNFgzOiEQvF2= NHXp[4xUSU6JRWK=
SCC-9 M{myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HuNWlEPTB;MUSuNVAzOSEQvF2= M1fsXHNCVkeHUh?=
KINGS-1 NVXGfmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor5TWM2OD1zND6xOFAzKM7:TR?= NEXRVWtUSU6JRWK=
SL-513 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF2LkG4O{DPxE1? NF\Ie|lUSU6JRWK=
HLE MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fJdWlEPTB;MUSuN|g2OiEQvF2= Mof4V2FPT0WU
SW1573 M1H1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TYNWlEPTB;MUSuOFQ{PSEQvF2= M4rhNnNCVkeHUh?=
KYSE-140 NX;vVHNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rBTmlEPTB;MUSuOlMzPyEQvF2= M3XGT3NCVkeHUh?=
SK-PN-DW MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe5XFlqUUN3ME2xOE45ODBzIN88US=> NV2yfZN6W0GQR1XS
A253 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\kTWM2OD1zNT6wOlI2KM7:TR?= MYfTRW5ITVJ?
CAL-12T M{TQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\MbmFnUUN3ME2xOU41PjZ{IN88US=> NGThfYVUSU6JRWK=
COLO-679 NWnCOG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7zdVBKSzVyPUG1Mlc3QDNizszN MofaV2FPT0WU
UACC-257 M{\CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwOpRKSzVyPUG2MlEzODFizszN M1zoXHNCVkeHUh?=
U-87-MG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjDfVNKSzVyPUG2MlM2OjNizszN NV3kdGJKW0GQR1XS
HCC1806 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ribGlEPTB;MU[uO|A4OSEQvF2= M{jXWnNCVkeHUh?=
NCI-H2170 M1XyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF5LkK0OFgh|ryP M{XRdnNCVkeHUh?=
AGS NFnmVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG3[mRuUUN3ME2xO{4{QDB6IN88US=> NF[wV|lUSU6JRWK=
MEL-HO NYH0eJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LlU2lEPTB;MUeuO|UxOyEQvF2= M1\xd3NCVkeHUh?=
SW48 NEHQTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn5W41bUUN3ME2xO{44PzF4IN88US=> NXXzeJRMW0GQR1XS
HuP-T4 NYH2dFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn2WmtvUUN3ME2xPE4xOjB4IN88US=> MXrTRW5ITVJ?
NCI-H720 NWHsUlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml76TWM2OD1zOD6xOFAzKM7:TR?= M3rBNnNCVkeHUh?=
RCC10RGB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfXbmtKSzVyPUG4MlE3QTdizszN NEHSPJRUSU6JRWK=
HD-MY-Z NFPNV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljzTWM2OD1zOD6yNlU1KM7:TR?= NVT3TphpW0GQR1XS
A427 MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPNcZZVUUN3ME2xPE42ODl2IN88US=> MlruV2FPT0WU
HCC2998 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\yd2FKSzVyPUG4MlYxPTFizszN MofPV2FPT0WU
EPLC-272H M3nEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqxTWM2OD1zOT6wOFM1KM7:TR?= MXjTRW5ITVJ?
C32 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKbVJKSzVyPUG5MlA1PSEQvF2= M{TY[3NCVkeHUh?=
UMC-11 NIfhNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF7LkKxNlMh|ryP NUfjN5pvW0GQR1XS
CaR-1 NUe3WpJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfyTWM2OD1zOT62PFA1KM7:TR?= MXrTRW5ITVJ?
KYSE-410 M3GxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO1fZZqUUN3ME2xPU46OTN7IN88US=> NH\YR2ZUSU6JRWK=
HuCCT1 NHToPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3iwUGlEPTB;MkCuOlI6PCEQvF2= NHPl[GlUSU6JRWK=
LB996-RCC NYPTWpo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf2W3BKSzVyPUKwMlcyPjhizszN NE\wXZpUSU6JRWK=
KYSE-70 NU\MfFV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrpSJRKSzVyPUKwMlgxPTlizszN Mn70V2FPT0WU
CAL-72 NGj5dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF72fGdKSzVyPUKwMlkyPSEQvF2= MXnTRW5ITVJ?
Capan-2 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\oeZAyUUN3ME2yNU4xPDF|IN88US=> Mo\DV2FPT0WU
PANC-08-13 M1rESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrQfHlKSzVyPUKxMlI2OTVizszN M2nKd3NCVkeHUh?=
SBC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf6TWM2OD1{MT6zNFgyKM7:TR?= NXy0PJZ{W0GQR1XS
MFM-223 NXe1UYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnJWXVKSzVyPUKxMlM{PDJizszN NX2zd4F6W0GQR1XS
BB49-HNC M2nTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jONGlEPTB;MkGuOVcyPiEQvF2= M3\jXHNCVkeHUh?=
SH-4 M3jI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJzLk[2NVgh|ryP NVXueGxQW0GQR1XS
HuO9 NYj6N2hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJzLkm4NlUh|ryP NInvVXFUSU6JRWK=
AM-38 NILsVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ{LkC0PFUh|ryP NHzXfoNUSU6JRWK=
A431 NHuxbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ|LkKxNVkh|ryP NUfpWnZTW0GQR1XS
YAPC NF7VbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDTWM2OD1{Mz6yOlUyKM7:TR?= MUfTRW5ITVJ?
LU-139 NIPIW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H2eGlEPTB;MkOuOFgxQSEQvF2= MVzTRW5ITVJ?
HEC-1 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULkO5lCUUN3ME2yN{41QTN5IN88US=> Mn3sV2FPT0WU
SCC-25 NHvVNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7MVXdKSzVyPUK0MlMxODZizszN NUfadFJvW0GQR1XS
HT-29 NVX0VItuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD1{ND6zPFI{KM7:TR?= M3j2VXNCVkeHUh?=
PC-14 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\uRZg3UUN3ME2yOE43PTdzIN88US=> NH32cIlUSU6JRWK=
Calu-6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H0OWlEPTB;MkWuOVA4OSEQvF2= NF23PVZUSU6JRWK=
SJRH30 NEXTSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ3Lk[0PVYh|ryP MXfTRW5ITVJ?
ChaGo-K-1 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPSTWM2OD1{Nj6xOlI6KM7:TR?= Mn\xV2FPT0WU
IA-LM NHzKNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrzeJpKSzVyPUK2MlM3PDVizszN NWTtNllUW0GQR1XS
GP5d NEGwWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXkTWM2OD1{Nj60OFkyKM7:TR?= MXrTRW5ITVJ?
NCI-H2291 NEDqe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm3[4NIUUN3ME2yOk43PTRzIN88US=> Ml3mV2FPT0WU
BALL-1 Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;HTWM2OD1{Nj65N|k4KM7:TR?= NFyxeJBUSU6JRWK=
HCC1954 NIXsXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3zfGhKSzVyPUK2Mlk5ODhizszN M4HJe3NCVkeHUh?=
NCI-H2452 M3;F[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPZTWM2OD1{Nz60NVY{KM7:TR?= MVzTRW5ITVJ?
LU-99A NXrCPXlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0dWlEPTB;MkeuOVU5OiEQvF2= MUfTRW5ITVJ?
NTERA-S-cl-D1 M2iwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTLTWM2OD1{Nz63Nlk6KM7:TR?= NYO2ZYt6W0GQR1XS
PANC-10-05 NH6yXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTXcYNpUUN3ME2yO{44Pzd3IN88US=> NEjMR3NUSU6JRWK=
NCI-H2405 M1fzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7aNI9KSzVyPUK3Mlk{QDdizszN M3rHW3NCVkeHUh?=
MDA-MB-415 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqzTWM2OD1{OD60NVM4KM7:TR?= MWDTRW5ITVJ?
NCI-H2342 NHrPcm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfBTWM2OD1{OD61NlgyKM7:TR?= MmTlV2FPT0WU
TGBC24TKB NILKNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ6LkexNVch|ryP NHHOSohUSU6JRWK=
LU-134-A M2e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LUOWlEPTB;MkiuPVI3OSEQvF2= NXXtWXRMW0GQR1XS
SCC-4 NW\lWVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zX[mlEPTB;M{GuNFQ6PCEQvF2= MVLTRW5ITVJ?
Saos-2 NEjwcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDLUIJKSzVyPUOxMlk{ODZizszN MX3TRW5ITVJ?
RERF-LC-MS M2\xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK3UIVoUUN3ME2zNk45OjNzIN88US=> NFm2UWZUSU6JRWK=
M14 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nOUmlEPTB;M{KuPVc3PCEQvF2= M{DmeXNCVkeHUh?=
HPAF-II NYf2VXduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN|LkWwNVEh|ryP M1ixTnNCVkeHUh?=
NCI-H1755 NGP5UoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\mUGlEPTB;M{SuN|MxPSEQvF2= MVnTRW5ITVJ?
D-392MG M2XQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN3Lki2O|Qh|ryP NX3jZ4V5W0GQR1XS
A704 M4POOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD1|Nj6wOFI4KM7:TR?= MmTZV2FPT0WU
CP50-MEL-B NWPpOFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnjSnVKSzVyPUO2MlE6OTFizszN M2jC[3NCVkeHUh?=
EW-18 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TsZ2lEPTB;M{[uOFUzKM7:TR?= M1ridnNCVkeHUh?=
WM-115 NG[5bGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrVZohKSzVyPUO2MlgxQTlizszN NH33SoJUSU6JRWK=
LU-65 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnHdnVKSzVyPUO3MlE1OTdizszN MlXkV2FPT0WU
NCI-H1563 NULwd4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n5fWlEPTB;M{euNlQ5PCEQvF2= M33DcnNCVkeHUh?=
DBTRG-05MG MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1UG9XUUN3ME2zPE4xPjlzIN88US=> MljHV2FPT0WU
NCI-H630 NX3wSXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1NmlEPTB;M{iuOFcyPCEQvF2= MUPTRW5ITVJ?
NCI-H1155 NIHONYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv2TWM2OD1|OT6yOFIh|ryP NUPrR41sW0GQR1XS
OVACR-3 MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnWc3RKSzVyPUO5MlkyQTVizszN MXXTRW5ITVJ?
OAW-42 NVTDdo5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUVlhKSzVyPUSwMlQzPThizszN M37hO3NCVkeHUh?=
JVM-2 NYntemZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrtfnFKSzVyPUSxMlI1OTVizszN MkLLV2FPT0WU
C3A NX;0[Y5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NVWlEPTB;NEGuN|Q1PyEQvF2= MXjTRW5ITVJ?
HT55 NVfDUHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7pcIZiUUN3ME20Nk4zQDRzIN88US=> M{WwTXNCVkeHUh?=
OVCAR-4 M1G2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTR{LkK5O|Qh|ryP M{H3OXNCVkeHUh?=
MEG-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR{LkS2NVYh|ryP M3rkb3NCVkeHUh?=
NCI-H82 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLiTWM2OD12Mz65PFkzKM7:TR?= MVjTRW5ITVJ?
JEG-3 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTQTWM2OD12ND65OFch|ryP M{LNbHNCVkeHUh?=
BPH-1 M3my[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPCVYhKSzVyPUS2MlM6QThizszN NF3ic5JUSU6JRWK=
MPP-89 NFPSXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;XTWM2OD12Nz6yPFk5KM7:TR?= MkPvV2FPT0WU
ALL-PO NXHWU5VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLzTWM2OD12Nz60NVg5KM7:TR?= NW\GUpVkW0GQR1XS
HT MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\mT|NXUUN3ME20O{41QTJizszN MWTTRW5ITVJ?
NCI-H2347 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR6LkC3NVUh|ryP NYHqfGhtW0GQR1XS
A2780 NWDIfYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7kfIpzUUN3ME20PU41OjJ6IN88US=> NEfUNVVUSU6JRWK=
KARPAS-299 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITXNGlKSzVyPUS5MlUyOTlizszN Mn72V2FPT0WU
NCI-H1651 Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrjXmZbUUN3ME20PU45QDJzIN88US=> MnzXV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method: Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol <1 mg/mL
In vivo Saline 20 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02730429 Not yet recruiting Endometrial Cancer Nordic Society for Gynaecologic Oncology|ENGOT|GCIG August 2016 Phase 2
NCT02778685 Not yet recruiting Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Recurrent Breast Carcinoma|Stage IV Breast Cancer City of Hope Medical Center|National Cancer Institute (NCI) July 2016 Phase 2
NCT02738866 Not yet recruiting Metastatic Breast Cancer Sidney Kimmel Comprehensive Cancer Center|Pfizer July 2016 Phase 2
NCT02668666 Recruiting Hormone Receptor Positive Malignant Neoplasm of Breast|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Metastatic Breast Cancer Oana Danciu, MD|Pfizer|Hoosier Cancer Research Network|Big Ten Cancer Research Consortium June 2016 Phase 2
NCT02806050 Not yet recruiting Breast Cancer University Medical Center Groningen June 2016 Phase 2
NCT02692755 Recruiting Hormone Receptor Positive HER-2 Negative Breast Cancer Georgetown University|University of Alabama at Birmingham|Hackensack University Medical Center June 2016 Phase 2|Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    There are two kind of Palbociclibs available: the isethionate salt or the HCl salt. I would like to know which is the main difference between them and what are they more suitable for in terms of experiment type (cell culture or in vivo animals experiments).

  • Answer:

    This two compounds are different Palbociclib salt. S1579 is the Isethionate salt, and the S1116 is the HCl salt. you can use S1116 for oral administration while S1579 is more suitable for I.P. administration.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID